Upgrade to SI Premium - Free Trial

Eli Lilly (LLY) sell-off 'overdone' on CVS move on Wegovy - Leerink

May 2, 2025 9:33 AM
Leerink Partners analyst David Risinger reiterated an Outperform rating and $944.00 price target on Eli Lilly (NYSE: LLY), saying yesterday's ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot Comments

Next Articles